Moderna has secured FDA approval for its respiratory syncytial virus (RSV ... and Pfizer’s products. There’s still one more step before Moderna’s vaccine can take on Arexvy and Abrysvo ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Pfizer is also running a phase 3 trial of Abrysvo in adults aged 18 to 59 at elevated risk of RSV disease due to chronic medical conditions, but data from that isn't due until later this year.

With the safePICO self-fill blood gas syringe, you can improve your mixing and get results you can trust. Mixing ball helps you obtain a homogeneous sample SafeTIPCAP minimizes the risk of blood ...

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

Scotland launched an RSV vaccination programme in August last year, using the Pfizer ABRYSVO vaccine, with local adults inviting aged between 75 and 79 to come forward for their free RSV vaccination ...